Calibr, a division of Scripps Research

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Calibr, a division of Scripps Research sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 4 completed early-phase tilt upper quartile by trial count

Calibr, a division of Scripps Research: 7 sponsored US clinical trials, 2 recruiting.

Calibr, a division of Scripps Research sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Transformed Follicular Lymphoma, with 1 trials.

Upper-quartile sponsor footprint

Calibr, a division of Scripps Research sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 2

CLF065 for Chronic Pouchitis

NCT07226050
RECRUITING Phase 1

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

NCT06878248
COMPLETED Phase 1

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906
COMPLETED Phase 1

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354
COMPLETED Phase 1

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

NCT04450069
TERMINATED Phase 1

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04077021
COMPLETED Phase 1

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

NCT03133676

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 1

Therapeutic Areas

Transformed Follicular Lymphoma 1
Relapsed/Refractory B-cell Lymphomas 1
Pouchitis 1
Malignant Neoplasm of Breast 1
Locally Advanced Breast Cancer (LABC) 1
Primary Mediastinal Large B Cell Lymphoma 1
Waldenstrom Macroglobulinemia 1
Marginal Zone Lymphoma (MZL) 1
Follicular Lymphoma (FL) 1
Diffuse Large B Cell Lymphoma (DLBCL) 1

What is open in the Calibr, a division of Scripps Research pipeline

2 recruiting of 7 indexed (29% open); 4 completed (57%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Transformed Follicular Lymphoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Calibr, a division of Scripps Research: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

Calibr, a division of Scripps Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share Calibr, a division of Scripps Research3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
Calibr, a division of Scripps Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Calibr, a division of Scripps Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Calibr, a division of Scripps Research page

7 registered trials is a research-attention snapshot, not an endorsement of Calibr, a division of Scripps Research or any single study.

  • 2 of Calibr, a division of Scripps Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Transformed Follicular Lymphoma is the condition Calibr, a division of Scripps Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Transformed Follicular Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Calibr, a division of Scripps Research pipeline card: 7 registered trials from official public datasets.Report a data error.